Analysis

Simcere Pharmaceutical Group Limited (2096) Stock Analysis

Simcere Pharmaceutical Group Limited investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to 2096.

website2096/analysis/2096

Simcere Pharmaceutical Group Limited

Simcere Pharmaceutical Group Limited investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to 2096.

Stock profile

Ticker

2096

Asset type

Stock

Market cap

$3.18B

Sector

Health Technology

Industry

Pharmaceuticals: Major

Currency

HKD

Ticker listings

Simcere Pharmaceutical Group Limited may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

2096 primary listing
SMHGF
A2QD9S
S2P

Latest Simcere Pharmaceutical Group Limited news

Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease

Simcere Pharmaceutical Group Ltd. ("Simcere") (HKEX: 2096) and Boehringer Ingelheim, today announced a license and collaboration agreement to develop SIM0709, a pre-clinical TL1...

Simcere's IL-2 Mutant Fusion Protein SIM0278 Entered Phase II Clinical Trial Stage

Simcere Pharmaceutical Group (2096.HK) announced that its regulatory T cells（Treg）-preferential IL-2 mutant Fc fusion protein (IL-2 mu-Fc), SIM0278, has officially entered a Pha...

NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States

First U.S. patient dosed at a mid-tier dose level where multiple responses have been observedMulti-regional trial to accelerate time to proof-of-concept data in 1H 2026 BELTSVIL...

Simcere Zaiming Announces First Patient Dosed in the US in a Phase 1 Trial of Trispecific Antibody SIM0500 in Patients with Relapsed/Refr...

Simcere Zaiming, an innovative oncology-focused subsidiary of Simcere Pharmaceutical Group (2096.HK) today announced the first US patient has started treatment in the ongoing Ph...

NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6

NextCure gains global rights to SIM0505 excluding greater China, where Simcere Zaiming will retain rightsPhase 1 clinical trial ongoing for SIM0505 in China; U.S. Phase 1 clinic...

Simcere Pharmaceutical Group Limited (2096) Stock Analysis